Session Details

Speakers, titles, times, and locations of ASGCT presentations

Detailed Program

CAR T and Other Genetically Modified Immune Cells

Session Details



88: Development of a FAP-CAR T Cell Protocol to Reduce Skeletal Muscle Fibrosis in a Murine Model of Duchenne Muscular Dystrophy

89: Genetic Depletion of TIGIT Augments CAR-NK Cell Effector Function in the Solid Tumor Microenvironment

90: HLA-A2 CAR/IL-2-CISC Engineered Treg Exhibit Robust In Vitro and In Vivo Efficacy

91: Anti-B7-H3 Chimeric Antigen Receptor NK Cells Suppress the Growth of Atypical Teratoid / Rhabdoid Tumor Orthotopic Xenografts

92: An Immune Synapse-Stabilizing Receptor Enhances Sensitivity of CAR- and TCR-Mediated Tumor Targeting

93: Transduction with Bicistronic CD20 CAR with NIS Reporter Allows PET/CT Visualization of CAR-T Cell Trafficking In Vivo

94: Chimeric Cytokine Receptors Induce Antigen-Specific Activation in Natural Killer Cells Against Acute Myeloid Leukemia

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.